Calidi Biotherapeutics (CLDI) Price & Analysis

Q: What was Calidi Biotherapeutics’s price range in the past 12 months?

Calidi Biotherapeutics lowest stock price was $1.10 and its highest was $22.68 in the past 12 months.

Q: What is Calidi Biotherapeutics’s market cap?

Calidi Biotherapeutics’s market cap is $9.75M.

Q: When is Calidi Biotherapeutics’s upcoming earnings report date?

Calidi Biotherapeutics’s upcoming earnings report date is Mar 13, 2026 which is in 80 days.

Q: How were Calidi Biotherapeutics’s earnings last quarter?

Calidi Biotherapeutics released its earnings results on Nov 13, 2025. The company reported -$2.21 earnings per share for the quarter, missing the consensus estimate of -$1.68 by -$0.53.

Q: Is Calidi Biotherapeutics overvalued?

According to Wall Street analysts Calidi Biotherapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Calidi Biotherapeutics pay dividends?

Calidi Biotherapeutics does not currently pay dividends.

Q: What is Calidi Biotherapeutics’s EPS estimate?

Calidi Biotherapeutics’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Calidi Biotherapeutics have?

Calidi Biotherapeutics has 7,167,721 shares outstanding.

Q: What happened to Calidi Biotherapeutics’s price movement after its last earnings report?

Calidi Biotherapeutics reported an EPS of -$2.21 in its last earnings report, missing expectations of -$1.68. Following the earnings report the stock price went down -1.316%.

Q: Which hedge fund is a major shareholder of Calidi Biotherapeutics?

Currently, no hedge funds are holding shares in CLDI

Compare

357 Followers

CLDI Stock Chart & Stats

$1.40

-$0.04(-2.72%)

At close: Jan 08 4:00 PM EST

$1.40

-$0.04(-2.72%)

Day’s Range― - ―

52-Week Range$1.10 - $22.68

Previous CloseN/A

Volume567.49K

Average Volume (3M)164.15K

Market Cap

$9.75M

Enterprise Value$6.88M

Total Cash (Recent Filing)$10.38M

Total Debt (Recent Filing)$3.11M

Price to Earnings (P/E)―

Beta0.70

Next Earnings

Mar 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.21

Shares Outstanding7,167,721

10 Day Avg. Volume193,319

30 Day Avg. Volume164,153

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)5.98

Price to Sales (P/S)0.00

P/FCF Ratio-0.47

Enterprise Value/Market Cap0.71

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.25

Enterprise Value/Ebitda-0.38

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DataEarly clinical data with a single dose of lead agent CLD-101 showed a near doubling of PFS and OS in some glioma patients.

Regulatory ApprovalThe FDA has cleared Northwestern University’s IND application for Calidi’s NeuroNova (CLD-101).

Bears Say

Financial StabilityGiven the company's financial situation, even after the offering, there appears to be meaningful risk to the company continuing as a going concern.

Calidi Biotherapeutics News

Calidi Biotherapeutics Raises $6.9 Million in Offering

Calidi Biotherapeutics ( ($CLDI) ) has issued an announcement. Calidi Biotherapeutics reported its third quarter 2025 financial results...

1M ago

CLDI

Calidi Biotherapeutics Unveils New Data on CLD-401

Calidi Biotherapeutics ( ($CLDI) ) has provided an update. On November 7, 2025, Calidi Biotherapeutics presented new data...

1M ago

CLDI

Calidi presents new data on CLD-401 at 2025 SITC annual meeting

Calidi (CLDI) Biotherapeutics presented new data on its first therapeutic candidate from its RedTail platform, CLD-401, at the...

1M ago

CLDI

Calidi Biotherapeutics Sells Majority Stake in Nova Cell

Calidi Biotherapeutics ( ($CLDI) ) just unveiled an announcement. On October 27, 2025, Calidi Biotherapeutics entered into agreements...

2M ago

CLDI

Calidi announces new data to be presented on CLD-401 at 2025 SITC meeting

Calidi (CLDI) Biotherapeutics announced the presentation of new data on its first therapeutic candidate from its RedTail platform,...

2M ago

CLDI

Calidi Biotherapeutics Forms New Advisory Board

The latest update is out from Calidi Biotherapeutics ( ($CLDI) ). On October 22, 2025, Calidi Biotherapeutics announced...

2M ago

CLDI

Calidi announces formation of its Scientific Advisory Board

Calidi (CLDI) Biotherapeutics announced the formation of its Scientific Advisory Board, SAB. The SAB will work with Calidi...

2M ago

CLDI

Calidi Biotherapeutics Streamlines Leadership with Role Elimination

Calidi Biotherapeutics ( ($CLDI) ) just unveiled an update. On September 16, 2025, Calidi Biotherapeutics‘ Board of Directors...

3M ago

CLDI

Calidi Biotherapeutics Updates Presentation Disclosure

Calidi Biotherapeutics ( ($CLDI) ) just unveiled an update. On August 29, 2025, Calidi Biotherapeutics, Inc. released an...

4M ago

CLDI

Calidi Biotherapeutics Completes $6.9M Public Offering

An announcement from Calidi Biotherapeutics ( ($CLDI) ) is now available. On August 20, 2025, Calidi Biotherapeutics announced...

4M ago

CLDI

Calidi prices 1.47M units at $2.00 in underwritten public offering

Calidi (CLDI) Biotherapeutics announced the pricing of an underwritten public offering for gross proceeds of $6M prior to...

4M ago

CLDI

Calidi files to sell 1.2M common stock units

Ladenburg Thalmann is acting as sole bookrunner for the offering. Laidlaw & Company is co-manager. Published first on...

4M ago

CLDI

Calidi Biotherapeutics Announces Executive Departure Agreement

Calidi Biotherapeutics ( ($CLDI) ) has issued an update. Calidi Biotherapeutics, Inc. announced the elimination of the position...

4M ago

CLDI

Calidi Biotherapeutics Secures FDA Fast Track Designation

Calidi Biotherapeutics ( ($CLDI) ) has issued an update. In the second quarter of 2025, Calidi Biotherapeutics reported...

5M ago

CLDI

CLDI FAQ

What was Calidi Biotherapeutics’s price range in the past 12 months?

Calidi Biotherapeutics lowest stock price was $1.10 and its highest was $22.68 in the past 12 months.

What is Calidi Biotherapeutics’s market cap?

Calidi Biotherapeutics’s market cap is $9.75M.

When is Calidi Biotherapeutics’s upcoming earnings report date?

Calidi Biotherapeutics’s upcoming earnings report date is Mar 13, 2026 which is in 80 days.

How were Calidi Biotherapeutics’s earnings last quarter?

Calidi Biotherapeutics released its earnings results on Nov 13, 2025. The company reported -$2.21 earnings per share for the quarter, missing the consensus estimate of -$1.68 by -$0.53.

Is Calidi Biotherapeutics overvalued?

According to Wall Street analysts Calidi Biotherapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Calidi Biotherapeutics pay dividends?

Calidi Biotherapeutics does not currently pay dividends.

What is Calidi Biotherapeutics’s EPS estimate?

Calidi Biotherapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Calidi Biotherapeutics have?

Calidi Biotherapeutics has 7,167,721 shares outstanding.

What happened to Calidi Biotherapeutics’s price movement after its last earnings report?

Calidi Biotherapeutics reported an EPS of -$2.21 in its last earnings report, missing expectations of -$1.68. Following the earnings report the stock price went down -1.316%.

Which hedge fund is a major shareholder of Calidi Biotherapeutics?

Currently, no hedge funds are holding shares in CLDI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Calidi Biotherapeutics

Calidi Biotherapeutics (CLDI) is a biotechnology company focusing on the development of innovative oncolytic virus-based therapies for cancer treatments. The company leverages proprietary technology platforms to enhance the therapeutic potential of oncolytic viruses, aiming to improve cancer treatment outcomes. Calidi Biotherapeutics operates within the biopharmaceutical sector, with its primary focus on developing immuno-oncology therapies targeting various cancer types.